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Abstract
Background: Plague is an ectoparasite-borne deadly infection caused by Yersinia pestis, a bacterium classified among the
group A bioterrorism agents. Thousands of deaths are reported every year in some African countries. Tetracyclines and
cotrimoxazole are used in the secondary prophylaxis of plague in the case of potential exposure to Y. pestis, but
cotrimoxazole-resistant isolates have been reported. There is a need for additional prophylactic measures. We aimed to
study the effectiveness of lovastatin, a cholesterol-lowering drug known to alleviate the symptoms of sepsis, for plague
prophylaxis in an experimental model.
Methodology: Lovastatin dissolved in Endolipide was intraperitoneally administered to mice (20 mg/kg) every day for 6
days prior to a Y. pestis Orientalis biotype challenge. Non-challenged, lovastatin-treated and challenged, untreated mice
were also used as control groups in the study. Body weight, physical behavior and death were recorded both prior to
infection and for 10 days post-infection. Samples of the blood, lungs and spleen were collected from dead mice for direct
microbiological examination, histopathology and culture. The potential antibiotic effect of lovastatin was tested on blood
agar plates.
Conclusions/Significance: Lovastatin had no in-vitro antibiotic effect against Y. pestis. The difference in the mortality
between control mice (11/15; 73.5%) and lovastatin-treated mice (3/15; 20%) was significant (P,0.004; Mantel-Haenszel
test). Dead mice exhibited Y. pestis septicemia and inflammatory destruction of lung and spleen tissues not seen in
lovastatin-treated surviving mice. These data suggest that lovastatin may help prevent the deadly effects of plague. Field
observations are warranted to assess the role of lovastatin in the prophylaxis of human plague.
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Introduction
Yersinia pestis is a Gram-negative bacillus belonging to the family
Enterobacteriaceae. It is responsible for deadly bubonic, pneumonic
and septicemic plagues [1,2] and is classified as a group A
bioterrorism agent (CDC, Atlanta, GA). Africa remains the
continent reporting the highest number of human plague cases
per year, with the Democratic Republic of the Congo declaring
1,700 to 2,000 cases and Madagascar declaring 500 to 600 cases to
the World Health Organization each year [http://www.who.int/
csr/don/archive/disease/plague/en/]. Experimental animal
models have indicated that, after inoculation, Y. pestis rapidly
escapes containment in the lymph node, spreads systemically
through the blood and produces fatal sepsis [2]. Sepsis occurs
when the immune system of the host responds to a localized
infection at a systemic level and thereby causes tissue damage and
organ dysfunction [3]. Clinical observations indicated that statins,
which are competitive inhibitors of hydroxymethylglutaryl-coen-
zyme A (HMG-CoA) [4,5], could prevent infections and reduced
mortality during severe sepsis [6]. Recent animal data has
confirmed that the administration of statins before a sepsis-
inducing insult reduced morbidity and improved survival [7,8]. No
data have been published regarding the potential role of statins in
the prevention of mortality during plague. We therefore tested
whether lovastatin, a statin obtained from fungal fermentation,
could significantly reduce the mortality associated with plague in
an experimental mouse model.
Materials and Methods
Ethics Statement
All studies were reviewed and approved by the Institutional
Animal Care and Use Committee at the Medical Faculty of
Marseille.
Bacterial strain and in vitro testing of lovastatin
susceptibility
Y. pestis strain 6/69M biotype Orientalis, a virulent isolate
originally from Madagascar (kindly provided by Prof. Michel
Simonet, Institut Pasteur, Lille, France) was grown on 5% sheep-
blood agar (BioMe ´rieux, Marcy l’Etoile, France) at 28uC under a
5% CO2 atmosphere for 2 days before use. The in-vitro antibiotic
activity of lovastatin (Sigma Aldrich, Saint-Quentin Fallavier,
France) was checked by pipetting 100 ml of a 4 mg/ml lovastatin/
Endolipide (B. Braun Melsungen AG, France) solution into two
0.5-cm
3 wells of a 5% sheep-blood agar plate (BioMe ´rieux)
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e10928inoculated with Y. pestis 6/69M Orientalis. Plates were then
incubated at 30uC for two days to check for any inhibition zone
around the lovastatin wells. The experiment was performed in
triplicate.
Animals and experimental protocol
A total of 45 six- to eight-week-old (16–18 g) female BALB/c mice
were purchased from Charles River Laboratories (Saint-Aubin-les-
Elbeuf, France). Animals were housed in BSL3 containment for 3–5
days before treatment. As a preliminary control, 3 mice were injected
intraperitoneally with 100 mL Endolipide alone; these mice remained
alive and symptom-free for 7 days. For treatment, one group of 15
animals was injected intraperitoneally with Endolipide every 24 h for
6 days (group A, Y. pestis 6/69M control group); a second group of 15
animals was injected intraperitoneally with 20 mg/kg lovastatin
solubilized in Endolipide every 24 h for 6 days (group B, prophylaxis
group); a third group of 15 mice were injected intraperitoneally with
20 mg/kg lovastatin solubilized in Endolipide (group C, lovastatin
control group) and were also maintained throughout the experiment.
Groups A and B were challenged with Y. pestis 6/69M 6 hours after
the last lovastatin injection by intraperitoneal injection of 100 mlo fa
10
8 cfu/ml suspension of Y. pestis 6/69M in PBS. Inoculated animals
were observed for the development of signs of lethal plague disease,
including lossof body weight, altered physical behavior and death, for
a period of 10 days. After the observation period, the remaining
animals were humanely euthanized by CO2 asphyxiation, a method
approved by the Panel on Euthanasia of the American Veterinary
Medical Association. Euthanized animals were necropsied and blood
was drawn by cardiac puncture.
Detection of Y. pestis
Blood samples collected by intracardiac puncture 24 to
48 hours p.i. from dead mice were spotted on a slide, spread
using another slide and air dried at room temperature. Slides were
fixed in 100% methanol for 10 min and stained with freshly
prepared acridine orange in the dark for 5 min [9]. Slides were
then rinsed with tap water, air dried at room temperature, overlaid
with DAPI (49,6 9-diamidino-2-phenylindole) ready-to-use solution
(Molecular Probes, Montluc ¸on, France) and examined using a
Leica DM 2500 upright fluorescence microscope at 1006
magnification with a FITC-rhodamine double band filter. A
second blood drop was deposited on a slide with a pen nib for
indirect immunofluorescence detection using an anti-Y. pestis
rabbit polyclonal antibody and FITC-conjugated goat anti-rabbit
IgG (Immunotech, Marseille, France) diluted at 1:400 in PBS
containing 3% non-fat dry milk and 0.2% Evans blue (BioMe ´r-
ieux, Marcy l’Etoile, France). Slides were washed, air dried and
mounted with Fluoroprep (BioMe ´rieux) and then examined under
a Olympus BX-51 epifluorescence microscope at 1006 magnifi-
cation. A third drop of blood was inoculated on a blood agar plate
(BioMe ´rieux) and incubated at 28uC in a 5% CO2 atmosphere for
2 days. To identify the colonies as Y. pestis, DNA was extracted
from the colonies using the QIAGEN-QIAamp DNA Mini Kit
according to the manufacturer protocol (QIAGEN S. A.
Courtaboeuf, France) for PCR amplification of the plasminogen-
activator gene pla [10]. PCR was carried out in the Applied
Biosystems 2720 thermal cycler (MJ Research, Waltham, Mass).
For the reaction, 1 mg/ml of the DNA preparation was amplified in
a 50-ml reaction mixture containing 10 mM Tris-HCl (pH 8.4),
50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs (Invitrogen,
Gaithersburg, Md.), 0.1 mM primer (Eurogentec S A, Seraing,
Belgium) and 1 U of Taq DNA polymerase (Invitrogen) at a final
volume of 50 ml. pla gene amplification was performed using an
initial 5-min denaturation step at 95uC and 39 cycles of 1-min
denaturation at 94uC, 30-s annealing at 60uC and 1-min extension
at 74uC followed by a final 15-min extension at 75uC. Sterilized
water was used as a negative control in each PCR assay and no
positive control was used. PCR products were purified using the
multi-screen PCR filter plate (Millipore, Saint-Quentin en
Yvelines, France). Sequencing reactions were performed using
the d-Rhodamine Terminator Cycle Sequencing Ready Reaction
kit with Amplitaq polymerase FS (Perkin-Elmer, Coignie `res,
France) and the sequencing products were resolved using an
ABI 3100 automated sequencer (Perkin-Elmer). Sequence analysis
was performed using the ABI prism DNA sequencing analysis
software package version 3.0 (Perkin-Elmer) on a Power
Macintosh 7200/120. The GenBank database was referenced
via the internet with BLAST software from the National Center
for Biotechnology Information homepage (http://www.ncbi.nlm.
nih.gov/BLAST/) and the sequence results were compared.
Pathological analyses
After the mice died, the lungs and the spleen were removed,
fixed with 4% buffered formalin and embedded in paraffin. Serial
sections (3 mm) of tissue specimens were obtained for routine
hematoxylin-eosin-saffron (HES) and Giemsa staining.
Mantel-Haenszel chi-square test
The Mantel-Haenszel test [11] was used to compare the
outcomes of the groups. The numerical values of live and dead
mice were entered into the table, and the statistical test was
performed. A p value ,0.05 was considered significant.
Results
In vitro susceptibility of Y. pestis to lovastatin
Sequencing the pla gene (100% sequence identity with GenBank
accession number AL109969.1) confirmed identification of this
strain at the time of the experiment. In vitro testing indicated that
Y. pestis grew when in contact with lovastatin-containing wells.
Mouse clinical data
A total of 11/15 (73.5%) control group A mice inoculated with
Y. pestis died within 48 hours post injection (p.i.), whereas 3/15
(20%) of the lovastatin group B mice died over a 10-day
observation period (P,0.004) (Figure 1). In both groups,
inoculated mice exhibited hair loss and a decreased appetite,
which was not observed in mice from control group C. In the Y.
pestis-infected control group A, weight decreased from 15.
8g 60.4 g at the time of inoculation to 15.0 g60.4 g at 24 h
p.i. and 14.6 g60.4 g at 48 h p.i., whereas the lovastatin control
group C mice demonstrated an increase in weight from
16.160.4 g at the time of inoculation to 19.160.4 g at the end
of the 10-day observation period. The weight of the lovastatin-
treated group B mice increased from 16.260.4 g at the time of
lovastatin treatment to 17.160.4 g during the of 6-day lovastatin
treatment period and then decreased 0.960.2 g after 48 h after
the Y. pestis challenge, gradually increasing to 18.960.4 g by the
end of the 10-day observation period.
Microbiological and pathology data
Microscopy detected acridine orange stained Y. pestis in the blood
(Figure2)andlungtissueof11/15(73.5%)groupAmice,aswellasin
3/15 (20%) group B mice, but not in group C mice. In mice from
groups A and B, culturing the blood and lung tissue resulted in
colonies identified as Y. pestis by pla sequence amplification, whereas
cultures of blood and lung tissue from group C mice remained sterile.
With group A mice, further microscopic examination demonstrated
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of the larger bronchi were still visible. Along with extensive
hemorrhages with large foci of necrosis, large numbers of neutrophils
were packed within the remaining pulmonary interstitium. The
spleen showed extensive necrosis and neutrophilic infiltration.
Giemsa-stained bacteria were observed in great numbers in the
pulmonary interstitial vessels and connective tissues but not in the
alveolar spaces or in the lumen of bronchi. Large numbers of
extracellular bacteria were also seen in the spleen, mainly in the red
pulp. In contrast, group B mice that survived Y. pestis challenge
presented no damage in the lungs and spleen. The pulmonary
interstitium and the splenic pulp showed no inflammatory infiltrates
or necrosis,and there were no bacteria detected by Giemsa staining
(Figure 3).
Discussion
In the conditions of this experimental study, lovastatin
significantly protected animals against a deadly challenge with
the plague agent Y. pestis. In this study, the intraperitoneal route
was used for producing a rapidly fatal, disseminated infection in
mice as previously reported [12]. In this study, lovastatin was
administrated by the parenteral route in order to ensure the
dosage. Because lovastatin is not readily soluble in aqueous
solution, we dissolved it in Endolipide, a lipidic solution also
licensed for parenteral administration in humans. We did ensure
that intraperitoneal Endolipide had no deleterious effect on mice
and did not protect mice from deadly plague.
After Y. pestis challenge, both control and lovastatin-treated mice
exhibited symptoms of plague, including loss of appetite and
decreased weight, but most of the lovastatin-treated mice
recovered 48 hours after Y. pestis challenge, whereas three-quarters
of the untreated animals died. Dead mice were all bacteremic with
characteristic lesions in the lungs and spleen, whereas the
surviving, lovastatin-treated mice had no bacteremia and no
pathological lesions in their organs in day-10 after challenge; as
transient bacteremia was not surveyed in this study, it was not
possible to assess the role of lovastatin in preventing dissemination
of Y. pestis. Indeed, we did not observe any direct antibacterial
effect of lovastatin-Endolipide using in vitro tests, which is in
Figure 1. Histogram of mortality in groups of 15 mice challenged with Y. pestis and injected with PBS (group A) or lovastatin (group
B); or challenged with lovastatin only (group C).
doi:10.1371/journal.pone.0010928.g001
Figure 2. Acridine orange staining of blood from dead group B mice (a; original magnification, 1006) showing Y. pestis organisms.
No organisms were found in the blood of the lovastatin-treated mice that survived the Y. pestis challenge (b; original magnification, 1006).
doi:10.1371/journal.pone.0010928.g002
Statine and Plague
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e10928agreement with the fact that the Y. pestis genome does not encode
HMG-CoA reductase, the molecular target for lovastatin [12–16].
These data therefore suggest that lovastatin had no direct effect on
inoculated Y. pestis organisms but, rather, exhibited anti-Yersinia
activity after Y. pestis organisms came into contact with host cells.
Accordingly, a previous study showed that lovastatin had no effect
on the growth of Salmonella enterica Typhimurium in broth but
caused a significant reduction in its intracellular growth in RAW
264.7 murine macrophages [8]. Also, lovastatin was shown to
lower the growth of the strictly intracellular Coxiella burnetii and
Rickettsia conorii when co-cultivated with the murine fibroblast L929
cell line [17,18].
The data reported herein are of interest regarding the
prophylactic treatment of plague. Primary prophylaxis aims to
prevent contact with Y. pestis by relying on barrier measures,
including avoiding areas with known epizootic plague, avoiding
animals appearing to be sick or dead, avoiding exposure to fleas
from diseased rats by avoiding places that are infested with rats or
where large numbers of rats have reportedly died, using protective
clothes and repellents to avoid exposure to ectoparasites when
outdoors and applying insect repellent containing DEET to legs
and ankles. Additional preventive methods include applying
repellents and insecticides to clothes and outer bedding, using
gloves for the manipulation of carcasses and cooking meat on an
open-flame grill or on a clam-shell type electric grill [19]. In the
case of potential contact with the plague agent, secondary
prophylaxis relies on the rapid administration of selected
antibiotics comprised of tetracyclines and cotrimoxazole [20]. Y.
pestis organisms are susceptible to most antibiotics that are active
against gram-negative organisms, except for imipenem, rifampin
and macrolides [21–23], but a clinical Y. pestis isolate from
Madagascar has been reported to be resistant to ampicillin,
chloramphenicol, kanamycin, streptomycin, spectinomycin, sul-
fonamides, tetracycline and minocycline [24]. A second clinical
isolate resistant to streptomycin has been further characterized in
Madagascar [25]. In both isolates, resistance genes were carried by
a transferable plasmid [25]. Based on experimental data gathered
in fleas, it has been hypothesized that horizontal gene transfer in
the flea may have been the source of such antibiotic-resistant Y.
pestis strains [26]. Such resistance includes resistance to antibiotics
used in the secondary prophylaxis of human plague [20]. Also, Y.
pestis isolates resistant to fluoroquinolones have been easily selected
by experimental growth in the presence of the targeted antibiotic
[20,27–29], and the selection of streptomycin-resistant strains has
been observed in an experimental model of pneumonic plague
treated with streptomycin [30]. These data indicate both a
potential for populations to be exposed to a natural or engineered
antimicrobial-resistant Y. pestis strain and the probable failure of
current prophylaxis schemes based on antibiotics [31].
With respect to this eventuality, field observations measuring
plague incidence and severity would be warranted to assess the
potential of lovastatin for lowering plague incidence and severity in
individuals receiving lovastatin as part of anticholesterol treatment,
and exposed to plague endemic countries.
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